Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29165922 | 1.00 | NR1H2 (0.56) | NR1H2USP2SMN1; SMN2DDB1CRBN | |
| SCHEMBL1005767 | 1.00 | NR1H2 (0.56) | NR1H2USP2SMN1; SMN2DDB1CRBN | |
| SCHEMBL1005536 | 1.00 | NR1H2 (0.56) | NR1H2USP2SMN1; SMN2DDB1CRBN | |
| SCHEMBL64564 | 1.00 | NR1H2 (0.56) | NR1H2USP2SMN1; SMN2DDB1CRBN | |
| Hydrochloric Acid SCHEMBL28576538 | 0.98 | NR1H2 (0.54) | NR1H2USP2SMN1; SMN2DDB1CRBN | |
| SCHEMBL25669757 | 0.90 | NR1H2 (0.50) | NR1H2USP2SMN1; SMN2DDB1CRBN | |
| SCHEMBL28455854 | 0.88 | NR1H2 (0.49) | NR1H2USP2SMN1; SMN2DDB1CRBN | |
| SCHEMBL27256391 | 0.88 | NR1H2 (0.49) | NR1H2USP2SMN1; SMN2DDB1CRBN | |
| SCHEMBL22972577 | 0.87 | NR1H2 (0.55) | NR1H2USP2SMN1; SMN2DDB1CRBN | |
| SCHEMBL30384932 | 0.87 | NR1H2 (0.55) | NR1H2USP2SMN1; SMN2DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 500 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3433239-B1 | SMALL MOLECULE INHIBITORS OF THE NUCLEAR TRANSLOCATION OF ANDROGEN RECEPTOR FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | UNIV YALE (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4100410-B1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES INC (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4712961-A2 | KRAS G12S AND G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-20260078134-A1 | Macrocyclic Compounds as RAS Inhibitors | BEONE MEDICINES I GMBH (CH) | 2026-03-19 | — | — | US | disclosed |
| US-20260042759-A1 | INHIBITOR CONTAINING BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) | 2026-02-12 | — | — | US | disclosed |
| US-20260008783-A1 | MODULATORS OF FSHR AND USES THEREOF | GEDEON RICHTER PLC (HU) | 2026-01-08 | — | — | US | disclosed |
| US-20260001875-A1 | AMINOPYRIMIDINYL DERIVATIVES FOR THE TREATMENT OF PARKINSON'S DISEASE | UNIV DUNDEE (GB) | 2026-01-01 | — | — | US | disclosed |
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-12473294-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| CN-1533382-A | Piperazine derivatives | - | 2004-09-29 | — | — | CN | disclosed |
| EP-1343775-A2 | PIPERAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-09-17 | — | — | EP | disclosed |
| US-6495549-B1 | 1-HETEROARYL-PIPERIDINE DERIVATIVES; MODERATING NEURONAL DEGENERATION; PROMOTING NEURONAL REGENERATION AND OUTGROWTH; TREATOG NEUROLOGICAL DISORDERS ARISING FROM NEURODEGENERATIVE DISEASES OR OTHER DISORDERS INVOLVING NERVE DAMAGE | PFIZER INC | 2002-12-17 | — | — | US | disclosed |
| US-20020143020-A1 | Novel piperazine derivatives | VERNALIS RESEARCH LIMITED (GB) | 2002-10-03 | — | — | US | disclosed |
| WO-2002048124-A2 | PIPERAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-20 | — | — | WO | disclosed |
| US-6235731-B1 | REDUCING BLOOD LIPIDS, SUGARS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-05-22 | — | — | US | disclosed |
| US-5686610-A | Pyridyl piperazine compound | PHARMACIA & UPJOHN COMPANY (US) | 1997-11-11 | — | — | US | disclosed |
| US-5599930-A | Substituted indoles as anti-AIDS pharmaceuticals | THE UPJOHN COMPANY (US) | 1997-02-04 | — | — | US | disclosed |
| EP-0594702-A1 | SUBSTITUTED INDOLES AS ANTI-AIDS PHARMACEUTICALS. | UPJOHN CO (US) | 1994-05-04 | — | — | EP | disclosed |
| WO-1993001181-A1 | SUBSTITUTED INDOLES AS ANTI-AIDS PHARMACEUTICALS | THE UPJOHN COMPANY (US) | 1993-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078134-A1 | Macrocyclic Compounds as RAS Inhibitors | NRAS, KRAS, HRAS | NR1H2 4524/4885USP2 2700/4885SMN1; SMN2 1533/4885 |
| US-20260008783-A1 | MODULATORS OF FSHR AND USES THEREOF | FSHR, GNRHR, LHCGR | NR1H2 44/4885USP2 4010/4885SMN1; SMN2 3474/4885 |
| US-20260042759-A1 | INHIBITOR CONTAINING BICYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF | FAR1, CYP4A11, CYP11B1 | NR1H2 83/4885USP2 4521/4885SMN1; SMN2 3634/4885 |
| US-20020143020-A1 | Novel piperazine derivatives | CYP4B1, UGT1A1, CYP1B1 | NR1H2 1100/4885USP2 3635/4885SMN1; SMN2 1517/4885 |
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | NR1H2 2595/4885USP2 1042/4885SMN1; SMN2 3173/4885 |
| US-20260001875-A1 | AMINOPYRIMIDINYL DERIVATIVES FOR THE TREATMENT OF PARKINSON'S DISEASE | LRRK2, XIAP, PARK7 | NR1H2 4081/4885USP2 189/4885SMN1; SMN2 563/4885 |
| US-12473294-B2 | Selective modulators of mutant LRRK2 proteolysis and associated methods of use | LRRK2, ADRM1, CRBN | NR1H2 4187/4885USP2 39/4885SMN1; SMN2 464/4885 |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, VHL, ADRM1 | NR1H2 2847/4885USP2 18/4885SMN1; SMN2 2142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.